An evaluation of serum paraoxonase together with arylesterase activities and oxidative stress in children with intractable epilepsy: A cross-sectional study

Epilepsy Research

Volumn 108, Issue 9, 2014, Pages 1591-1596

  Calik, Mustafa ^a   Oguz, Elif ^a   Sarikaya, Suna ^a   Kocaturk, Ozcan ^a   Koca, Bulent ^a   Gungor, Hatice Eke ^a   Aksoy, Nurten ^a   Yoldas, Tahir Kurtulus ^a   Iscan, Akin ^b  

^a HARRAN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b BEZMIALEM VAKIF UNIVERSITY   (Turkey)

Author keywords

Arylesterase; Atherosclerosis; Epilepsy; Oxidative stress; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CREATININE; ETIRACETAM; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMOTRIGINE; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; SODIUM; TOPIRAMATE; TRIACYLGLYCEROL; UREA; VALPROIC ACID; ARYLDIALKYLPHOSPHATASE; CARBOXYLESTERASE;

ARTICLE; BLOOD SAMPLING; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; ELECTROENCEPHALOGRAPHY; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INTRACTABLE EPILEPSY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION; OXIDATIVE STRESS; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCHOOL CHILD; SODIUM BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; BLOOD; DIET RESTRICTION; EPILEPSY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CHILD; CROSS-SECTIONAL STUDIES; ELECTROENCEPHALOGRAPHY; EPILEPSY; FASTING; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; OXIDATIVE STRESS;

EID: 84907967169     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2014.08.007     Document Type: Article

References (37)

1. Arts W.F., Brouwer O.F., Peters A.C., Stroink H., Peeters E.A., Schmitz P.I., et al. Course and prognosis of childhood epilepsy: 5-year follow-up of the Dutch study of epilepsy in childhood. Brain 2004, 127:1774-1784.
2. Aslan M., Kosecik M., Horoz M., Selek S., Celik H., Erel O. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. Atherosclerosis 2007, 191:397-402.
3. Belcastro V., Gaetano G., Italiano D., Oteri G., Caccamo D., Pisani L.R., et al. Antiepileptic drugs and MTHFR polymorphisms influence hyper-homocysteinemia recurrence in epileptic patients. Epilepsia 2007, 48:1990-1994.
4. Belcastro V., Striano P. Antiepileptic drugs, hyperhomocysteinemia and B-vitamins supplementation in patients with epilepsy. Epilepsy Res. 2012, 102:1-7.
5. Belcastro V., D'Egidio C., Striano P., Verrotti A. Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res. 2013, 107:1-8.
6. Berg A.T., Kelly M.M. Defining intractability: comparisons among published definitions. Epilepsia 2006, 47:431-436.
7. Berg A.T., Vickrey B.G., Testa F.M., Levy S.R., Shinnar S., DiMario F., et al. How long does it take for epilepsy to become intractable? A prospective investigation. Ann. Neurol. 2006, 60:73-79.
8. Blatter M.C., James R.W., Messmer S., Barja F., Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 1993, 211:871-879.
9. Bulut M., Selek S., Bez Y., Karababa I.F., Kaya M.C., Gunes M., et al. Reduced PON1 enzymatic activity and increased lipid hydroperoxide levels that point out oxidative stress in generalized anxiety disorder. J. Affect. Disord. 2013, 150:829-833.
10. Calik M., Abuhandan M., Kandemir H., Güzel B., Solmaz A., Celik H., et al. Interictal serum S-100B protein levels in intractable epilepsy: a case-control study. Neurosci. Lett. 2014, 558:58-61.
11. Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2001, 21:473-480.
12. Eckerson H.W., Wyte C.M., La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 1983, 35:1126-1138.
13. Emeksiz H.C., Serdaroglu A., Biberoglu G., Gulbahar O., Arhan E., Cansu A., et al. Assessment of atherosclerosis risk due to the homocysteine-asymmetric dimethylarginine-nitric oxide cascade in children taking antiepileptic drugs. Seizure 2013, 22:124-127.
14. Erdemir A., Cullu N., Yiş U., Demircioğlu F., Kir M., Cakmakçi H., et al. Evaluation of serum lipids and carotid artery intima media thickness in epileptic children treated with valproic acid. Brain Dev. 2009, 31:713-716.
15. Fujikawa D.G. Prolonged seizures and cellular injury: understanding the connection. Epilepsy Behav. 2005, 7:3-11.
16. Greenwood R.S. Adverse effects of antiepileptic drugs. Epilepsia 2000, 41:42-52.
17. Haagen L., Brock A. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur. J. Clin. Chem. Clin. Biochem. 1992, 30:391-395.
18. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 1992, 5:1609-1623.
19. Hamed S.A., Hamed E.A., Hamdy R., Nabeshima T. Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. Epilepsy Res. 2007, 74:183-192.
20. Jakubus T., Michalska-Jakubus M., Lukawski K., Janowska A., Czuczwar S.J. Atherosclerotic risk among children taking antiepileptic drugs. Pharmacol. Rep. 2009, 6:411-423.
21. Kabaroglu C., Mutaf I., Boydak B., Ozmen D., Habif S., Erdener D., et al. Association between serum paraoxonase activity and oxidative stres in acute coronary syndromes. Acta Cardiol. 2004, 59:606-611.
22. Kayani S., Sirsi D. The safety and tolerability of newer antiepileptic drugs in children and adolescents. J. Cent. Nerv. Syst. Dis. 2012, 8:51-63.
23. Keenan N., Sadlier L.G., Wiltshire E. Vascular function and risk factors in children with epilepsy: associations with sodium valproate and carbamazepine. Epilepsy Res. 2014, 108:1087-1094.
24. Mackness B., Durrington P.N., Boulton A.J., Hine D., Mackness M.I. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur. J. Clin. Invest. 2002, 32:259-264.
25. Nourooz-Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol. 1999, 300:58-62.
26. Stocker R., Keaney J.F. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 2004, 84:1381-1478.
27. Sutula T.P., Hagen J., Pitkanen A. Do epileptic seizures damage the brain?. Curr. Opin. Neurol. 2003, 16:189-195.
28. Tan T.Y., Lu C.H., Chuang H.Y., Lin T.K., Liou C.W., Chang W.N., et al. Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis. Epilepsia 2009, 50:1579-1586.
29. Tokgoz H., Aydin K., Oran B., Kiyici A. Plasma leptin, neuropeptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproate. Childs Nerv. Syst. 2012, 28:1049-1053.
30. Van Himbergen T.M., Van Tits L.J., Ter Avest E., Roest M., Voorbij H.A., de Graaf J., et al. Paraoxonase (PON1) is associated with familial combined hyperlipidemia. Atherosclerosis 2008, 199:87-94.
31. Varoglu A.O., Yildirim A., Aygul R., Gundogdu O.L., Sahin Y.N. Effects of valproate, carbamazepine, and levetiracetam on the antioxidant and oxidant systems in epileptic patients and their clinical importance. Clin. Neuropharmacol. 2010, 33:155-157.
32. Verrotti A., Scardapane A., Franzoni E., Manco R., Chiarelli F. Increased oxidative stress in epileptic children treated with valproic acid. Epilepsy Res. 2008, 78:171-177.
33. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 1995, 96:2882-2891.
34. Witztum J.L. The oxidation hypothesis of atherosclerosis. Lancet 1994, 344:793-795.
35. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 1991, 88:1785-1792.
36. Yildiz A., Sezen Y., Gur M., Yilmaz R., Demirbag R., Erel O. Association of paraoxonase activity and coronary collateral flow. Coron. Artery Dis. 2008, 19:441-447.
37. Yildiz M., Simsek G., Uzun H., Uysal S., Sahin S., Balci H. Assessment of low-density lipoprotein oxidation, paraoxonase activity, and arterial distensibility in epileptic children who were treated with anti-epileptic drugs. Cardiol. Young 2010, 20:547-554.